Reaction
Radiation Injury reporting signals
As of the last recalculation, Radiation Injury appears in 1,050 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is BICALUTAMIDE (PRR 21.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bicalutamide | 16 | 21.1 | 21.1 |
| Temozolomide | 22 | 21.1 | 21.1 |
| Abiraterone | 12 | 17.7 | 17.7 |
| Leuprolide Acetate | 64 | 17.4 | 17.4 |
| Gefitinib | 7 | 15.5 | 15.5 |
| Anastrozole Tablets | 16 | 15.0 | 15.0 |
| Anastrozole | 25 | 13.8 | 13.8 |
| Ribociclib | 21 | 13.4 | 13.4 |
| Cisplatin | 49 | 13.0 | 13.0 |
| Letrozole | 38 | 12.7 | 12.7 |
| Abemaciclib | 12 | 12.0 | 12.0 |
| Vemurafenib | 7 | 11.6 | 11.6 |
| Palbociclib | 51 | 11.1 | 11.1 |
| Cetuximab | 17 | 10.9 | 10.9 |
| Bendamustine Hcl | 7 | 9.0 | 9.0 |
| Enzalutamide | 26 | 9.0 | 9.0 |
| Abiraterone Acetate | 16 | 7.8 | 7.8 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 8 | 6.8 | 6.8 |
| Rucaparib | 3 | 6.8 | 6.8 |
| Relugolix | 7 | 5.9 | 5.9 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 5.9 | 5.9 |
| Durvalumab | 6 | 5.9 | 5.9 |
| Trifluridine And Tipiracil | 3 | 5.6 | 5.6 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 3 | 4.5 | 4.5 |